CP-07

• Description :

  CP-07 is a potent and selective PROTACCDK9 degrader (DC50: 43 nM) . CP-07 inhibits 22RV1 cell proliferation (IC50: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer[1].

• UNSPSC :

  12352005

• Target :

  CDK; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; PROTAC

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cp-07.html

• Solubility :

  10 mM in DMSO

• Smiles :

  COC1=CC(O)=C(C(C=C(C2=CC=C(N3CCN(CC4CCN(C5=CC=C(C(N(C6CCC(NC6=O)=O)C7=O)=O)C7=C5)CC4)CC3)C=C2)O8)=O)C8=C1C9=CCN(C)CC9

• Molecular Formula :

  C45H48N6O8

• Molecular Weight :

  800.90

• References & Citations :

  [1]Wu T, et al. Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy. Eur J Med Chem. 2023 Nov 15;260:115774.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK9